Literature DB >> 24670575

Impact of chronic renal failure on anti-tuberculosis treatment outcomes.

P Baghaei1, M Marjani1, P Tabarsi1, A Moniri1, F Rashidfarrokhi2, F Ahmadi3, A-A Nassiri2, M-R Masjedi3, A A Velayati1, A Cattamanchi4.   

Abstract

SETTING: National Referral Centre for Tuberculosis (TB), Tehran, Iran.
OBJECTIVE: To determine the impact of chronic renal failure (CRF) on TB treatment outcomes.
DESIGN: A retrospective study was conducted among adult TB patients with CRF and age- and sex-matched TB controls without CRF treated at the National Research Institute of Tuberculosis and Lung Disease from 2004 to 2011. Multivariate analysis was performed to determine the impact of CRF on drug-induced hepatitis (DIH), treatment failure and all-cause mortality.
RESULTS: A total of 55 TB cases with CRF and 165 TB cases without CRF were included in the study. Baseline demographic and clinical characteristics were similar, except that TB cases with CRF were more likely to be of Iranian nationality (94.5% vs. 83%, P = 0.04). During anti-tuberculosis treatment, 40 (18.2%) patients developed DIH, none failed treatment and 15 (6.8%) died. Patients with CRF were more likely to develop DIH (27.3% vs. 15.2%, P = 0.04) and to die during treatment (16.4% vs. 3.6%, P = 0.001). CRF remained significantly associated with all-cause mortality (HR 4.87, 95%CI 1.73-13.65) in multivariate analysis, whereas the relationship with DIH was not.
CONCLUSION: TB patients with CRF are at increased risk of death. More intensive monitoring of patients with CRF should be considered by the National TB Programme.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24670575     DOI: 10.5588/ijtld.13.0726

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Tuberculosis Burden and Determinants of Treatment Outcomes According to Age in Brazil: A Nationwide Study of 896,314 Cases Reported Between 2010 and 2019.

Authors:  Beatriz Barreto-Duarte; Mariana Araújo-Pereira; Betânia M F Nogueira; Luciana Sobral; Moreno M S Rodrigues; Artur T L Queiroz; Michael S Rocha; Vanessa Nascimento; Alexandra B Souza; Marcelo Cordeiro-Santos; Afrânio L Kritski; Timothy R Sterling; María B Arriaga; Bruno B Andrade
Journal:  Front Med (Lausanne)       Date:  2021-07-27

2.  Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  Meijun Si; Huiqun Li; Yanru Chen; Hui Peng
Journal:  BMJ Case Rep       Date:  2018-05-18

3.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

4.  Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.

Authors:  Nicholas R Degner; Jann-Yuan Wang; Jonathan E Golub; Petros C Karakousis
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 20.999

5.  Clinical features in pulmonary tuberculosis patients combined with diabetes mellitus in China: An observational study.

Authors:  Xunliang Tong; Dingyi Wang; He Wang; Yixuan Liao; Yimeng Song; Yuanchun Li; Yue Zhang; Guohui Fan; Xuefeng Zhong; Yang Ju; Yanming Li
Journal:  Clin Respir J       Date:  2021-07-26       Impact factor: 1.761

6.  Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weighting.

Authors:  Gerardo Alvarez-Uria; Manoranjan Midde; Praveen K Naik
Journal:  PeerJ       Date:  2016-05-17       Impact factor: 2.984

7.  Real-world association of adherence with outcomes and economic burden in patients with tuberculosis from South Korea claims data.

Authors:  Sun-Hong Kwon; Jin Hyun Nam; Hye-Lin Kim; Hae-Young Park; Jin-Won Kwon
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

Review 8.  Tuberculosis treatment.

Authors:  Marcelo Fouad Rabahi; José Laerte Rodrigues da Silva Júnior; Anna Carolina Galvão Ferreira; Daniela Graner Schuwartz Tannus-Silva; Marcus Barreto Conde
Journal:  J Bras Pneumol       Date:  2017 Nov-Dec       Impact factor: 2.624

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.